Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    topical, THC
Previous Study | Return to List | Next Study

The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04741477
Recruitment Status : Not yet recruiting
First Posted : February 5, 2021
Last Update Posted : June 9, 2021
Sponsor:
Collaborator:
Substance Abuse and Mental Health Services Administration (SAMHSA)
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
This study will evaluate the pharmacokinetic and pharmacodynamic effects of hemp-based Cannabidiol (CBD) topical products (e.g., lotions, creams, patches) that contain low levels of delta-9-tetrahydrocannabinol (THC).

Condition or disease Intervention/treatment Phase
Cannabis Drug Effect Drug: CBD Drug: THC Drug: Placebo Phase 1

Detailed Description:

A total of 5 topical cannabinoid products will be examined in this study. The study will be conducted in 5 discrete stages, one for each product. In each stage, participants (N=20), will be randomized to 1 of 2 double-blind drug conditions that entail the use of: 1) a topical product that contains CBD and a low amount of THC (N=15), or 2) a placebo topical product that does not contain cannabinoids (N=5), but which contains similar non-cannabinoid ingredients to the active product. Thus, overall 100 participants will complete the study (75 active, 25 placebo).

Participants in each stage will complete a three-phase outpatient protocol that will last a total of 17 days. Phase 1 (Day 1) will be an acute laboratory dosing session (approximately 7 hours in duration). Phase 2 (Days 2-10) will be an outpatient dosing period, during which participants will continue to use participants' assigned product twice daily (morning and evening) in participants' own environment. During Phase 2, participants will visit the laboratory for brief study sessions on Days 2, 3, 7, and 10. Phase 3, will consist of a final follow-up visit on Day 17, after a 1-week drug washout. Pharmacokinetic and pharmacodynamic assessments (subjective and cognitive effects) will be assessed during each phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A total of 5 topical cannabinoid products will be examined in this study. The study will be conducted in 5 discrete stages, one for each product. In each stage, participants (N=20), will be randomized to 1 of 2 double-blind drug conditions that entail the use of: 1) a topical product that contains CBD and a low amount of THC (N=15), or 2) a placebo topical product that does not contain cannabinoids (N=5), but which contains similar non-cannabinoid ingredients to the active product.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products
Estimated Study Start Date : July 2021
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Arm Intervention/treatment
Experimental: Topical CBD Product with low level of THC
Participants will topically apply a high CBD-product that also contains low levels of THC.
Drug: CBD
CBD will be topically applied

Drug: THC
THC will be topically applied

Placebo Comparator: Placebo topical product
Participants will topically apply a placebo product that does not contain cannabinoids.
Drug: Placebo
a placebo product (without cannabinoids) will be topically applied




Primary Outcome Measures :
  1. Change in Urine cannabinoids [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Concentration of cannabinoids will be measured in urine (unit of measurement: nanograms/mL)

  2. Change in Blood cannabinoids [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Concentration of cannabinoids will be measured in blood (unit of measurement: nanograms/mL)


Secondary Outcome Measures :
  1. Change in Oral fluid cannabinoids [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Concentration of cannabinoids will be measured in oral fluid (unit of measurement: nanograms/mL)

  2. Change in Hair cannabinoids [ Time Frame: Days 1 and 17 ]
    Concentration of cannabinoids will be measured in hair (unit of measurement: nanograms/mL)

  3. Change in Subjective drug effects as assessed by the Drug Effect Questionnaire [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Subjective drug effect ratings (0-100) will be collected with the Drug Effect Questionnaire, with 0 being no effect and 100 being maximum effect.

  4. Change in Cognitive performance as assessed by the Divided Attention Task [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Cognitive performance will be evaluated with the Divided Attention Task. Will be measured as the mean distance (in computer pixels) of the mouse cursor from the central stimulus.

  5. Change in Working memory performance as assessed by the Paced Serial Addition Task [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Working memory performance will be evaluated with the Paced Serial Addition Task (scores can range from 0-90) with 90 indicating perfect performance.

  6. Change in Psychomotor performance as assessed by the Digit Symbol Substitution Task [ Time Frame: Days 1, 2, 3, 7, 10, and 17 ]
    Psychomotor performance will be evaluated with the Digit Symbol Substitution Task. Will be measured as the number of correct trials within 90 seconds.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Have provided written informed consent
  2. Be between the ages of 18 and 55
  3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
  4. Test negative for recent cannabis use in urine at the screening visit and again upon admission for each experimental session
  5. Test negative for other drugs of abuse, including alcohol, at the screening visit and upon arrival for each experimental session
  6. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.
  7. Have a body mass index (BMI) in the range of 19 to 36 kg/m^2
  8. Have head hair that is at least 4 cm (approximately one and a half inches) in length on the back of the head.
  9. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
  10. Report prior experience using cannabis or CBD products.
  11. Have not donated blood in the prior 30 days.
  12. Have a smart phone, tablet, computer, etc. capable of recording videos and operating Redcap.

Exclusion Criteria:

  1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.
  2. History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
  3. Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), vitamin(s), or prescription medications (with the exception of birth control prescriptions) within 14 days of study entry; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the subject.
  4. Use of hemp seeds or hemp oil in any form in the past 3 months.
  5. Use of dronabinol (Marinol) within the past 6 months.
  6. History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
  7. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
  8. Known allergy to any ingredients in the active or placebo topical products.
  9. Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.
  10. Epilepsy or a history of seizures.
  11. Individuals with anemia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04741477


Contacts
Layout table for location contacts
Contact: Tory Spindle, PhD 410-550-0529 tspindle@jhmi.edu

Sponsors and Collaborators
Johns Hopkins University
Substance Abuse and Mental Health Services Administration (SAMHSA)
Investigators
Layout table for investigator information
Principal Investigator: Tory Spindle, PhD Johns Hopkins University
Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT04741477    
Other Study ID Numbers: IRB00277556
1-340-0216610-65527L ( Other Grant/Funding Number: Substance Abuse And Mental Health Administration )
First Posted: February 5, 2021    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders